SCHEMBL3933138

SCHEMBL3933138

CCNCc1ccc(N/C(=C2\C(=O)Nc3cc(C(=O)OC)ccc32)c2ccc3c(c2)OC=CO3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 4/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
CASP1 P29466 1/20 0.35
ALOX5 P09917 1/20 0.35
RAB9A P51151 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MAPT P10636 2/20 0.34
MEN1 O00255 3/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
NPC1 O15118 2/20 0.34
CASP3 P42574 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3933145 1.00 LMNA (0.39) LMNAHPGDKMT2ACTDSP1CASP1
SCHEMBL3944374 0.89 MAPT (0.42) LMNAHPGDKMT2ARAB9ASMN1; SMN2
SCHEMBL3944362 0.89 MAPT (0.42) LMNAHPGDKMT2ARAB9ASMN1; SMN2
SCHEMBL5858365 0.89 BACE1 (0.36) LMNAHPGDKMT2ARAB9ASMN1; SMN2
SCHEMBL5858202 0.89 TP53 (0.34) KMT2ARAB9ASMN1; SMN2MAPTMEN1
SCHEMBL3940392 0.89 TP53 (0.34) KMT2ARAB9ASMN1; SMN2MAPTMEN1
SCHEMBL3940679 0.89 BACE1 (0.36) LMNAHPGDKMT2ARAB9ASMN1; SMN2
SCHEMBL3935228 0.87 MAPT (0.40) LMNAKMT2ACTDSP1CASP1ALOX5
SCHEMBL3935237 0.87 MAPT (0.40) LMNAKMT2ACTDSP1CASP1ALOX5
SCHEMBL3937069 0.87 KMT2A (0.36) KMT2ACTDSP1CASP1ALOX5RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 LMNA 1567/4885HPGD 1038/4885KMT2A 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.